NR 566 Midterm Exam: Pharmacology Questions & Answers(
Update) Advanced Pharmacology - Care of the Family |
Chamberlain University - 200 Questions
This exam assesses advanced understanding of pharmacokinetics and pharmacodynamics, focusing on drug
absorption, distribution, metabolism, excretion, receptor theory, and dose-response relationships. Questions
require integration of physiological principles with clinical application. It contains 200 multiple-choice questions,
each with four distractors and a fully worked rationale that explains why the keyed answer is correct. Content is
organized into 10 focused sections: Pharmacokinetics and Pharmacodynamics, Autonomic Nervous System
Drugs, Cardiovascular Pharmacology, Endocrine Pharmacology, Central Nervous System Drugs, Antimicrobial
Therapy, Respiratory Pharmacology, Gastrointestinal Pharmacology, Pain Management and Analgesics, Women's
Health and Reproductive Pharmacology. Targeted learning outcomes include: Predict how pathophysiological
changes alter drug disposition and response.; Apply pharmacokinetic principles to optimize drug therapy in
special populations.; Analyze receptor-mediated drug effects and their clinical implications.. Every item has been
reviewed for clinical accuracy, current guidelines, and clarity so that students can study with confidence and
self-correct as they work through the bank. Use it as a high-yield review immediately before the exam, or as a
structured practice tool during the unit - the rationales double as concise teaching notes. The recommended
writing time is 3 hours, with a passing score of 90%. Aligned with Accredited by the Commission on Collegiate
Nursing Education (CCNE) and consistent with US university standards for graduate-level pharmacology.
Section 1: Pharmacokinetics and Pharmacodynamics (Questions 1-20)
1 A drug with a high extraction ratio is primarily eliminated by the liver. Which of the following best describes
the impact of reduced hepatic blood flow on the clearance of this drug?
A) Clearance decreases proportionally to the reduction in blood flow because clearance is blood-flow limited.
B) Clearance increases due to reduced first-pass metabolism, leading to higher bioavailability.
C) Clearance remains unchanged because intrinsic clearance is the rate-limiting step.
D) Clearance decreases only if protein binding is also altered.
Answer: A
Rationale: For high extraction ratio drugs, hepatic clearance is primarily determined by liver blood flow (CL "H Q).
Reduced blood flow directly decreases clearance. Intrinsic clearance is less limiting. Options B and C are incorrect
because clearance does not increase and is not independent of flow. Option D is irrelevant as protein binding
changes have minimal effect on high extraction drugs.
2 A drug exhibits nonlinear pharmacokinetics due to saturable metabolism. Which of the following clinical
scenarios would most likely result in a disproportionate increase in steady-state concentration after a modest
dose increase?
A) A drug with a high volume of distribution and low clearance.
B) A drug that is a substrate of CYP3A4 with a high affinity.
C) A drug that undergoes first-order elimination at therapeutic doses.
D) A drug that is primarily eliminated by glomerular filtration.
Answer: B
Rationale: Saturable metabolism (e.g., involving high-affinity, low-capacity enzymes like CYP3A4 for some drugs)
leads to nonlinear kinetics: as dose increases, clearance decreases disproportionately, causing supratherapeutic
concentrations. Option A describes a drug with linear distribution. Option C is linear. Option D is typically linear
unless active secretion is involved.
,3 Which of the following pharmacokinetic parameters is most sensitive to changes in plasma protein binding for a
low extraction ratio drug that is highly protein bound (>90%)?
A) Volume of distribution (Vd)
B) Clearance (CL)
C) Half-life (t1/2)
D) Bioavailability (F)
Answer: A
Rationale: For low extraction ratio drugs, clearance is dependent on intrinsic clearance and free fraction, but volume
of distribution is directly proportional to free fraction. A decrease in protein binding increases free fraction,
markedly increasing Vd for highly bound drugs. Half-life may also change but is secondary. Bioavailability is
affected by first-pass, not binding.
4 A drug is a weak base with pKa 7.4. In a patient with metabolic alkalosis (blood pH 7.5), which of the following
changes in drug distribution is most likely?
A) Increased intracellular concentration due to ion trapping in acidic compartments.
B) Decreased volume of distribution because the drug becomes more ionized.
C) Increased renal clearance due to enhanced tubular reabsorption.
D) No change because pKa is equal to normal pH.
Answer: A
Rationale: Weak bases accumulate in acidic compartments (ion trapping). In alkalosis, extracellular pH is higher, so
the drug is more unionized and crosses membranes more readily; once inside cells (more acidic), it becomes
ionized and trapped, increasing intracellular concentration. Option B is opposite: Vd increases. Option C: alkalosis
reduces reabsorption of weak bases, increasing clearance. Option D: pKa = pH does not imply no change.
5 A drug follows a two-compartment model. After an IV bolus, the plasma concentration-time curve shows a
rapid initial decline followed by a slower terminal phase. Which of the following best explains the initial rapid
decline?
A) Distribution from central to peripheral compartment.
B) Elimination from the central compartment.
C) Metabolism in the peripheral compartment.
D) Redistribution back to the central compartment.
Answer: A
Rationale: In a two-compartment model, the rapid initial decline (alpha phase) is due to distribution of drug from the
central compartment (plasma) into the peripheral compartment (tissues). Elimination occurs more slowly during the
beta phase. Options B and C are incorrect as elimination is slower; D describes the opposite process.
6 Which of the following best describes the relationship between the therapeutic index (TI) and the slope of the
dose-response curve?
A) A steep dose-response curve narrows the TI because small dose changes cause large effects.
B) A shallow dose-response curve narrows the TI because large dose changes are needed for effect.
C) The TI is independent of the slope; it only depends on the median effective and toxic doses.
D) A steep dose-response curve widens the TI because the therapeutic window is larger.
Answer: A
Rationale: The therapeutic index (TI = TD50/ED50) is a ratio, but the slope of the dose-response curve influences
safety: a steep curve means small dose increments can move from subtherapeutic to toxic, effectively narrowing the
therapeutic window. Option B is opposite; C ignores slope's clinical relevance; D is incorrect.
, 7 A partial agonist at a receptor produces a maximal effect that is 60% of a full agonist. In the presence of a full
agonist, the partial agonist will:
A) Act as an antagonist, reducing the full agonist's effect.
B) Additively increase the effect to 160%.
C) Have no effect because it is less efficacious.
D) Potentiate the full agonist via allosteric modulation.
Answer: A
Rationale: A partial agonist has lower intrinsic efficacy. When co-administered with a full agonist, it competes for
receptors, reducing the number of receptors occupied by the full agonist, thereby decreasing the overall effect
(antagonistic behavior). Option B is incorrect because effects are not additive; C is wrong because it does have an
effect; D is not typical.
8 A drug has a volume of distribution of 500 L and a clearance of 50 L/hr. What is the approximate half-life?
A) 7 hours
B) 10 hours
C) 14 hours
D) 20 hours
Answer: A
Rationale: Half-life = 0.693 * Vd / CL = 0.693 * = 6.93 hours "H 7 hours. Options B, C, D result from
miscalculation (e.g., using Vd/CL directly or incorrect constant).
9 Which of the following scenarios best illustrates the concept of pharmacodynamic tolerance?
A) A patient requires higher doses of warfarin to achieve the same INR due to increased CYP2C9 activity.
B) A patient on morphine develops respiratory depression at lower doses after chronic use.
C) A patient on beta-blockers shows reduced heart rate response after dose escalation.
D) A patient on furosemide develops decreased diuretic effect due to hypertrophy of distal tubule cells.
Answer: D
Rationale: Pharmacodynamic tolerance refers to a diminished response to a drug due to adaptive changes at the
receptor or cellular level (e.g., downregulation, hypertrophy). Option A describes pharmacokinetic tolerance
(increased metabolism). Option B describes increased sensitivity, not tolerance. Option C describes expected
dose-response, not tolerance.
10 A drug is administered as a continuous IV infusion. The steady-state concentration (Css) is 10 mg/L. If the
infusion rate is doubled, which of the following is true regarding the time to reach new steady state?
A) Time to reach new steady state is unchanged because it depends only on half-life.
B) Time to reach new steady state is halved because the rate of rise increases.
C) Time to reach new steady state is doubled because the target concentration is higher.
D) Time to reach new steady state depends on the loading dose administered.
Answer: A
Rationale: The time to reach steady state is determined solely by the elimination half-life (about 4-5 half-lives).
Doubling the infusion rate increases Css but does not change the half-life or the time to reach new steady state.
Options B and C are incorrect; D is irrelevant as no loading dose is mentioned.
11 A patient with chronic kidney disease (eGFR 25 mL/min) is prescribed a drug that is primarily renally
eliminated and has a narrow therapeutic index. The drug's volume of distribution is 0.5 L/kg, and it is 90%
bound to albumin. Which pharmacokinetic parameter change is MOST likely to require a dosage adjustment in
this patient?
, A) Increased volume of distribution due to reduced albumin binding, leading to higher free drug concentration
B) Decreased clearance due to reduced renal function, leading to prolonged elimination half-life
C) Increased bioavailability due to reduced first-pass metabolism in the gut wall
D) Decreased protein binding due to uremic toxins, leading to reduced free fraction
Answer: B
Rationale: In chronic kidney disease, renal clearance is diminished, which directly reduces the elimination rate of
renally excreted drugs. This prolongs the half-life and necessitates dose reduction to avoid accumulation. While
protein binding may decrease, the primary concern is reduced clearance. Volume of distribution changes are less
predictable and often not the main driver for dosing adjustments.
12 A drug follows a two-compartment model after intravenous bolus administration. The initial rapid decline in
plasma concentration is followed by a slower terminal phase. Which statement BEST describes the relationship
between the distribution half-life (t½) and elimination half-life (t½)?
A) t½ is always shorter than t½ because distribution is faster than elimination
B) t½ is longer than t½ because drug redistributes from tissues back to plasma
C) Both half-lives are equal in a two-compartment model
D) t½ depends on the rate of metabolism, while t½ depends on renal clearance
Answer: A
Rationale: In a two-compartment model, the distribution phase (±) represents rapid equilibration between central
and peripheral compartments, which is faster than the elimination phase (). Thus t½ (distribution half-life) is shorter
than t½ (elimination half-life). The terminal half-life reflects elimination from the body, not redistribution.
13 A drug exhibits nonlinear pharmacokinetics due to saturable hepatic metabolism. At low doses, the half-life is 4
hours; at high doses, the half-life increases to 10 hours. Which of the following BEST explains this
observation?
A) Increased volume of distribution at high doses due to tissue saturation
B) Saturation of drug-metabolizing enzymes, leading to zero-order elimination at high concentrations
C) Decreased bioavailability at high doses due to increased first-pass metabolism
D) Increased renal clearance at high doses due to glomerular filtration rate changes
Answer: B
Rationale: Nonlinear pharmacokinetics often results from saturation of metabolic enzymes (e.g., CYP450). At high
doses, elimination shifts from first-order (proportional to concentration) to zero-order (constant rate), prolonging
half-life. Volume of distribution changes are not the primary cause. Renal clearance is typically linear unless active
secretion is saturated.
14 A drug with a high extraction ratio (E > 0.7) is administered orally. Which statement about its bioavailability is
CORRECT?
A) Bioavailability is primarily determined by the rate of absorption from the gastrointestinal tract
B) Bioavailability is low and highly variable because of extensive first-pass hepatic metabolism
C) Bioavailability is unaffected by hepatic blood flow because the drug is highly protein-bound
D) Bioavailability is high because high extraction ratio implies efficient absorption
Answer: B
Rationale: For high extraction ratio drugs, hepatic clearance is blood-flow limited, and extensive first-pass
metabolism reduces oral bioavailability significantly. Variability in hepatic blood flow and enzyme activity leads to
high interindividual variability. Absorption rate and protein binding have lesser impact on bioavailability for such
drugs.
Update) Advanced Pharmacology - Care of the Family |
Chamberlain University - 200 Questions
This exam assesses advanced understanding of pharmacokinetics and pharmacodynamics, focusing on drug
absorption, distribution, metabolism, excretion, receptor theory, and dose-response relationships. Questions
require integration of physiological principles with clinical application. It contains 200 multiple-choice questions,
each with four distractors and a fully worked rationale that explains why the keyed answer is correct. Content is
organized into 10 focused sections: Pharmacokinetics and Pharmacodynamics, Autonomic Nervous System
Drugs, Cardiovascular Pharmacology, Endocrine Pharmacology, Central Nervous System Drugs, Antimicrobial
Therapy, Respiratory Pharmacology, Gastrointestinal Pharmacology, Pain Management and Analgesics, Women's
Health and Reproductive Pharmacology. Targeted learning outcomes include: Predict how pathophysiological
changes alter drug disposition and response.; Apply pharmacokinetic principles to optimize drug therapy in
special populations.; Analyze receptor-mediated drug effects and their clinical implications.. Every item has been
reviewed for clinical accuracy, current guidelines, and clarity so that students can study with confidence and
self-correct as they work through the bank. Use it as a high-yield review immediately before the exam, or as a
structured practice tool during the unit - the rationales double as concise teaching notes. The recommended
writing time is 3 hours, with a passing score of 90%. Aligned with Accredited by the Commission on Collegiate
Nursing Education (CCNE) and consistent with US university standards for graduate-level pharmacology.
Section 1: Pharmacokinetics and Pharmacodynamics (Questions 1-20)
1 A drug with a high extraction ratio is primarily eliminated by the liver. Which of the following best describes
the impact of reduced hepatic blood flow on the clearance of this drug?
A) Clearance decreases proportionally to the reduction in blood flow because clearance is blood-flow limited.
B) Clearance increases due to reduced first-pass metabolism, leading to higher bioavailability.
C) Clearance remains unchanged because intrinsic clearance is the rate-limiting step.
D) Clearance decreases only if protein binding is also altered.
Answer: A
Rationale: For high extraction ratio drugs, hepatic clearance is primarily determined by liver blood flow (CL "H Q).
Reduced blood flow directly decreases clearance. Intrinsic clearance is less limiting. Options B and C are incorrect
because clearance does not increase and is not independent of flow. Option D is irrelevant as protein binding
changes have minimal effect on high extraction drugs.
2 A drug exhibits nonlinear pharmacokinetics due to saturable metabolism. Which of the following clinical
scenarios would most likely result in a disproportionate increase in steady-state concentration after a modest
dose increase?
A) A drug with a high volume of distribution and low clearance.
B) A drug that is a substrate of CYP3A4 with a high affinity.
C) A drug that undergoes first-order elimination at therapeutic doses.
D) A drug that is primarily eliminated by glomerular filtration.
Answer: B
Rationale: Saturable metabolism (e.g., involving high-affinity, low-capacity enzymes like CYP3A4 for some drugs)
leads to nonlinear kinetics: as dose increases, clearance decreases disproportionately, causing supratherapeutic
concentrations. Option A describes a drug with linear distribution. Option C is linear. Option D is typically linear
unless active secretion is involved.
,3 Which of the following pharmacokinetic parameters is most sensitive to changes in plasma protein binding for a
low extraction ratio drug that is highly protein bound (>90%)?
A) Volume of distribution (Vd)
B) Clearance (CL)
C) Half-life (t1/2)
D) Bioavailability (F)
Answer: A
Rationale: For low extraction ratio drugs, clearance is dependent on intrinsic clearance and free fraction, but volume
of distribution is directly proportional to free fraction. A decrease in protein binding increases free fraction,
markedly increasing Vd for highly bound drugs. Half-life may also change but is secondary. Bioavailability is
affected by first-pass, not binding.
4 A drug is a weak base with pKa 7.4. In a patient with metabolic alkalosis (blood pH 7.5), which of the following
changes in drug distribution is most likely?
A) Increased intracellular concentration due to ion trapping in acidic compartments.
B) Decreased volume of distribution because the drug becomes more ionized.
C) Increased renal clearance due to enhanced tubular reabsorption.
D) No change because pKa is equal to normal pH.
Answer: A
Rationale: Weak bases accumulate in acidic compartments (ion trapping). In alkalosis, extracellular pH is higher, so
the drug is more unionized and crosses membranes more readily; once inside cells (more acidic), it becomes
ionized and trapped, increasing intracellular concentration. Option B is opposite: Vd increases. Option C: alkalosis
reduces reabsorption of weak bases, increasing clearance. Option D: pKa = pH does not imply no change.
5 A drug follows a two-compartment model. After an IV bolus, the plasma concentration-time curve shows a
rapid initial decline followed by a slower terminal phase. Which of the following best explains the initial rapid
decline?
A) Distribution from central to peripheral compartment.
B) Elimination from the central compartment.
C) Metabolism in the peripheral compartment.
D) Redistribution back to the central compartment.
Answer: A
Rationale: In a two-compartment model, the rapid initial decline (alpha phase) is due to distribution of drug from the
central compartment (plasma) into the peripheral compartment (tissues). Elimination occurs more slowly during the
beta phase. Options B and C are incorrect as elimination is slower; D describes the opposite process.
6 Which of the following best describes the relationship between the therapeutic index (TI) and the slope of the
dose-response curve?
A) A steep dose-response curve narrows the TI because small dose changes cause large effects.
B) A shallow dose-response curve narrows the TI because large dose changes are needed for effect.
C) The TI is independent of the slope; it only depends on the median effective and toxic doses.
D) A steep dose-response curve widens the TI because the therapeutic window is larger.
Answer: A
Rationale: The therapeutic index (TI = TD50/ED50) is a ratio, but the slope of the dose-response curve influences
safety: a steep curve means small dose increments can move from subtherapeutic to toxic, effectively narrowing the
therapeutic window. Option B is opposite; C ignores slope's clinical relevance; D is incorrect.
, 7 A partial agonist at a receptor produces a maximal effect that is 60% of a full agonist. In the presence of a full
agonist, the partial agonist will:
A) Act as an antagonist, reducing the full agonist's effect.
B) Additively increase the effect to 160%.
C) Have no effect because it is less efficacious.
D) Potentiate the full agonist via allosteric modulation.
Answer: A
Rationale: A partial agonist has lower intrinsic efficacy. When co-administered with a full agonist, it competes for
receptors, reducing the number of receptors occupied by the full agonist, thereby decreasing the overall effect
(antagonistic behavior). Option B is incorrect because effects are not additive; C is wrong because it does have an
effect; D is not typical.
8 A drug has a volume of distribution of 500 L and a clearance of 50 L/hr. What is the approximate half-life?
A) 7 hours
B) 10 hours
C) 14 hours
D) 20 hours
Answer: A
Rationale: Half-life = 0.693 * Vd / CL = 0.693 * = 6.93 hours "H 7 hours. Options B, C, D result from
miscalculation (e.g., using Vd/CL directly or incorrect constant).
9 Which of the following scenarios best illustrates the concept of pharmacodynamic tolerance?
A) A patient requires higher doses of warfarin to achieve the same INR due to increased CYP2C9 activity.
B) A patient on morphine develops respiratory depression at lower doses after chronic use.
C) A patient on beta-blockers shows reduced heart rate response after dose escalation.
D) A patient on furosemide develops decreased diuretic effect due to hypertrophy of distal tubule cells.
Answer: D
Rationale: Pharmacodynamic tolerance refers to a diminished response to a drug due to adaptive changes at the
receptor or cellular level (e.g., downregulation, hypertrophy). Option A describes pharmacokinetic tolerance
(increased metabolism). Option B describes increased sensitivity, not tolerance. Option C describes expected
dose-response, not tolerance.
10 A drug is administered as a continuous IV infusion. The steady-state concentration (Css) is 10 mg/L. If the
infusion rate is doubled, which of the following is true regarding the time to reach new steady state?
A) Time to reach new steady state is unchanged because it depends only on half-life.
B) Time to reach new steady state is halved because the rate of rise increases.
C) Time to reach new steady state is doubled because the target concentration is higher.
D) Time to reach new steady state depends on the loading dose administered.
Answer: A
Rationale: The time to reach steady state is determined solely by the elimination half-life (about 4-5 half-lives).
Doubling the infusion rate increases Css but does not change the half-life or the time to reach new steady state.
Options B and C are incorrect; D is irrelevant as no loading dose is mentioned.
11 A patient with chronic kidney disease (eGFR 25 mL/min) is prescribed a drug that is primarily renally
eliminated and has a narrow therapeutic index. The drug's volume of distribution is 0.5 L/kg, and it is 90%
bound to albumin. Which pharmacokinetic parameter change is MOST likely to require a dosage adjustment in
this patient?
, A) Increased volume of distribution due to reduced albumin binding, leading to higher free drug concentration
B) Decreased clearance due to reduced renal function, leading to prolonged elimination half-life
C) Increased bioavailability due to reduced first-pass metabolism in the gut wall
D) Decreased protein binding due to uremic toxins, leading to reduced free fraction
Answer: B
Rationale: In chronic kidney disease, renal clearance is diminished, which directly reduces the elimination rate of
renally excreted drugs. This prolongs the half-life and necessitates dose reduction to avoid accumulation. While
protein binding may decrease, the primary concern is reduced clearance. Volume of distribution changes are less
predictable and often not the main driver for dosing adjustments.
12 A drug follows a two-compartment model after intravenous bolus administration. The initial rapid decline in
plasma concentration is followed by a slower terminal phase. Which statement BEST describes the relationship
between the distribution half-life (t½) and elimination half-life (t½)?
A) t½ is always shorter than t½ because distribution is faster than elimination
B) t½ is longer than t½ because drug redistributes from tissues back to plasma
C) Both half-lives are equal in a two-compartment model
D) t½ depends on the rate of metabolism, while t½ depends on renal clearance
Answer: A
Rationale: In a two-compartment model, the distribution phase (±) represents rapid equilibration between central
and peripheral compartments, which is faster than the elimination phase (). Thus t½ (distribution half-life) is shorter
than t½ (elimination half-life). The terminal half-life reflects elimination from the body, not redistribution.
13 A drug exhibits nonlinear pharmacokinetics due to saturable hepatic metabolism. At low doses, the half-life is 4
hours; at high doses, the half-life increases to 10 hours. Which of the following BEST explains this
observation?
A) Increased volume of distribution at high doses due to tissue saturation
B) Saturation of drug-metabolizing enzymes, leading to zero-order elimination at high concentrations
C) Decreased bioavailability at high doses due to increased first-pass metabolism
D) Increased renal clearance at high doses due to glomerular filtration rate changes
Answer: B
Rationale: Nonlinear pharmacokinetics often results from saturation of metabolic enzymes (e.g., CYP450). At high
doses, elimination shifts from first-order (proportional to concentration) to zero-order (constant rate), prolonging
half-life. Volume of distribution changes are not the primary cause. Renal clearance is typically linear unless active
secretion is saturated.
14 A drug with a high extraction ratio (E > 0.7) is administered orally. Which statement about its bioavailability is
CORRECT?
A) Bioavailability is primarily determined by the rate of absorption from the gastrointestinal tract
B) Bioavailability is low and highly variable because of extensive first-pass hepatic metabolism
C) Bioavailability is unaffected by hepatic blood flow because the drug is highly protein-bound
D) Bioavailability is high because high extraction ratio implies efficient absorption
Answer: B
Rationale: For high extraction ratio drugs, hepatic clearance is blood-flow limited, and extensive first-pass
metabolism reduces oral bioavailability significantly. Variability in hepatic blood flow and enzyme activity leads to
high interindividual variability. Absorption rate and protein binding have lesser impact on bioavailability for such
drugs.
